ASCO 2022: GVHD

Advertisement
DocWire News EditorsASCO 2022 | April 3, 2023
In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated ...
DocWire News EditorsASCO 2022 | October 16, 2023
According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host ...
DocWire News EditorsASCO 2022 | August 25, 2023
Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than ...
DocWire News EditorsASCO 2022 | October 16, 2023
The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell ...
DocWire News EditorsASCO 2022 | September 26, 2023
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting reported on results of a literature ...
DocWire News EditorsASCO 2022 | October 16, 2023
Patients who received an allogeneic hematopoietic stem cell transplant (HSCT) from matched related donors (MRD) or ...
DocWire News EditorsASCO 2022 | September 21, 2023
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric ...
DocWire News EditorsASCO 2022 | October 16, 2023
A retrospective study found that partially mismatched blood or marrow transplantation with post-transplantation ...
Advertisement